In the first quarter of 1992 Smith & Nephew made sales of L 201.1 million ($357.2 million), up 11% on the like, year-earlier period. The underlying increase was 8%. Pretax profit rose 9% to L 31.1 million, and earnings per share were 2.0 pence.
The results were said to reflect excellent progress in orthopedic and wound management products in the USA and in Europe. Eric Kinder, company chairman, said: "the first quarter's performance was in line with our expectations and confirms steady progress in our core health care businesses."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze